scholarly journals Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Laura C. D. Pomatto-Watson ◽  
Monica Bodogai ◽  
Oye Bosompra ◽  
Jonathan Kato ◽  
Sarah Wong ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Caloric Restriction ◽  
Standard Laboratory ◽  
Primary Tumor Growth ◽  
Cancer Model ◽  
Time Level ◽  
Immune Signature ◽  
Breast Cancer Model ◽  
Primary Driver ◽  
Tumor Growth And Metastasis

AbstractCancer incidence increases with age and is a leading cause of death. Caloric restriction (CR) confers benefits on health and survival and delays cancer. However, due to CR’s stringency, dietary alternatives offering the same cancer protection have become increasingly attractive. Short cycles of a plant-based diet designed to mimic fasting (FMD) are protective against tumorigenesis without the chronic restriction of calories. Yet, it is unclear whether the fasting time, level of dietary restriction, or nutrient composition is the primary driver behind cancer protection. Using a breast cancer model in mice, we compare the potency of daily CR to that of periodic caloric cycling on FMD or an isocaloric standard laboratory chow against primary tumor growth and metastatic burden. Here, we report that daily CR provides greater protection against tumor growth and metastasis to the lung, which may be in part due to the unique immune signature observed with daily CR.

scholarly journals PDK1 promotes tumor growth and metastasis in a spontaneous breast cancer model

Oncogene ◽  
2015 ◽  
Vol 35 (25) ◽  
pp. 3314-3323 ◽  
Author(s):  
J Du ◽  
M Yang ◽  
S Chen ◽  
D Li ◽  
Z Chang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Growth ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Tumor Growth And Metastasis

Combination therapy with carboplatin and thalidomide suppresses tumor growth and metastasis in 4T1 murine breast cancer model

2014 ◽  
Vol 68 (1) ◽  
pp. 51-57 ◽  
Author(s):  
Cristina Maria de Souza ◽  
Ana Cândida Araújo e Silva ◽  
Clarissa de Jesus Ferraciolli ◽  
Giovanna Vieira Moreira ◽  
Liliane Cunha Campos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Combination Therapy ◽  
Tumor Growth ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Tumor Growth And Metastasis

scholarly journals Piperine suppresses tumor growth and metastasis in vitro and in vivo in a 4T1 murine breast cancer model

2012 ◽  
Vol 33 (4) ◽  
pp. 523-530 ◽  
Author(s):  
Li-hua Lai ◽  
Qi-hong Fu ◽  
Yang Liu ◽  
Kai Jiang ◽  
Qing-ming Guo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Growth ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Tumor Growth And Metastasis

scholarly journals Temporal Changes in Immune Responses within the Tumor Microenvironment in the 4T1.2-HER2 Mammary Tumor Model

2021 ◽  
Author(s):  
Yitong Xu ◽  
Connie Rogers
Keyword(s):  
Immune Responses ◽  
Tumor Growth ◽  
Immune Cells ◽  
Tumor Regression ◽  
Tumor Model ◽  
Second Phase ◽  
Tumor Inoculation ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Initial Tumor

Abstract Background: The murine 4T1.2 triple-negative breast cancer model is widely used, but is poorly immunogenic with no defined tumor-associated antigens. A modified 4T1.2 model has been developed that stably expresses a surrogate tumor antigen, human epidermal growth factor receptor-2 (HER2). The goal of the current study was to characterize host immune responses in the 4T1.2-HER2 tumor model, focusing on the tumor microenvironment (TME) during the early stage of tumor development. Methods: Female BALB/c mice were orthotopically inoculated with 4T1.2-HER2 tumor cells and sacrificed at day (D) 6, 9, 12, 15 and 18 post tumor inoculation. The phenotype and function of tumor-infiltrating immune cells were assessed. Results: 4T1.2 and 4T1.2-HER2 tumor cells had similar proliferation rates in vitro. In contrast to the rapid progression of the parental 4T1.2 model, the 4T1.2-HER2 model demonstrated initial tumor growth followed by spontaneous tumor regression by D18 post tumor inoculation, which was not observed in scid mice. Following tumor regression, mice demonstrated either a second phase of tumor outgrowth or complete tumor rejection. Within the TME, the percentage of T cells was reduced at D9 and increased during tumor regression through D18 (p<0.05), whereas the percentage of myeloid-derived suppressor cells (MDSCs) increased during the initial tumor growth and was reduced by D18 (p<0.01). There was a stepwise increase in the percentage of IFNg+, IL-2+ and perforin+ T cells and NK cells peaking at D12-15. Furthermore, tumor regression occurred concurrently with HER2-specific IFNg production from tumor-infiltrating immune cells at D12 and D15 (p<0.05). During the second phase of 4T1.2-HER2 tumor growth, tumor volume was negatively correlated with immune infiltration (r=0.662, p=0.052). Conclusions: These results suggest that the integration of a surrogate tumor antigen, human HER2, into the clinically relevant, yet poorly immunogenic 4T1.2 breast cancer model enhanced its immunogenicity and induced HER2-specific immune responses.

scholarly journals Stretching Reduces Tumor Growth in a Mouse Breast Cancer Model

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
L. Berrueta ◽  
J. Bergholz ◽  
D. Munoz ◽  
I. Muskaj ◽  
G. J. Badger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Growth ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Mouse Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document